SCHEMBL5608240

SCHEMBL5608240

O=C(O)CC1(NI)CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
ALDH1A1 P00352 5/20 0.45
USP2 O75604 2/20 0.45
CYP1A2 P05177 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
BLM P54132 1/20 0.45
CACNA2D1 P54289 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD11B1 P28845 3/20 0.41
MAPK1 P28482 1/20 0.36
HPGD P15428 1/20 0.33
MME P08473 1/20 0.32
GAA P10253 2/20 0.32
ADRB2 P07550 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5608003 0.98 CYP2C19 (0.45) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL23895993 0.93 CYP2C19 (0.40) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL5019821 0.78 CYP2C19 (0.48) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL15798070 0.78 CYP2C19 (0.48) CYP2C19ALDH1A1USP2CYP1A2LMNA
Hydrochloric Acid SCHEMBL27856474 0.77 CYP2C19 (0.47) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL1825623 0.76 CYP2C19 (0.45) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL9162035 0.75 CYP2C19 (0.45) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL3667120 0.75 CYP2C19 (0.45) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL27608123 0.75 CYP2C19 (0.45) CYP2C19ALDH1A1USP2CYP1A2LMNA
SCHEMBL3369935 0.75 CYP2C19 (0.45) CYP2C19ALDH1A1USP2CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863477-A1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION Novartis AG (CH) 2007-12-12 EP disclosed
WO-2006100036-A1 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2006-09-28 WO disclosed